报价延迟最少15分钟:2026/03/09 19:51 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.23 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.32/-0.82
|
|
企业价值
195.84M
|
| 资产负债 |
|
每股账面净值
0.89
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
10.68M
|
|
每股收益
0.18
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner. |
